Log in to save to my catalogue

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparti...

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparti...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_96bea20f4a6e46d8a78a3f7c6943f262

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

The relative conservation of the influenza hemagglutinin (HA) stem compared to that of the immunodominant HA head makes the HA stem an attractive target for broadly protective influenza vaccines. Here we report the first-in-human, dose-escalation, open-label trial (NCT04579250) evaluating an unadjuvanted group 2 stabilized stem ferritin nanoparticl...

Alternative Titles

Full title

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_96bea20f4a6e46d8a78a3f7c6943f262

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_96bea20f4a6e46d8a78a3f7c6943f262

Other Identifiers

ISSN

2059-0105

E-ISSN

2059-0105

DOI

10.1038/s41541-024-00959-0

How to access this item